Sakmar, Debbie L. Hay, Lukas Grätz, and more. Check out some of the latest GPCR discoveries below!

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small molecules aimed at intractable and poorly drugged membrane and complex-bound protein targets. The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute carriers, are relevant to immunology indications and rare diseases with high unmet need." Read more at the source #DrGPCR #GPCR #IndustryNews

Hailong Zhang, PhD, Shanghai Yogar Therapeutics Dr.

Hay on class B GPCRs, RAMPs, and the selectivity problem in CGRP-targeted migraine therapies - what the approved drugs may still be getting wrong. << Back to podcast list Strategic Partner(s) Debbie Hay: ABOUT THE GUEST Hay is a professor of pharmacology at the University of Otago, New Zealand. Debbie Hay is presently a professor at the Department of Pharmacology and Toxicology at the University Debbie Hay on the web LinkedIn Wikipedia University of Otago University of Auckland Google Scholar Pubmed

Debbie Hay , University of Otago. Feb 2021 — Episode #27 released featuring Dr. Robert J.

Debbie Hay, Dr. Randy Hall, tributes toDr. Marc Caronwith over 30 guests includingDr.